IDYA
Price
$24.50
Change
-$0.33 (-1.33%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
2.17B
18 days until earnings call
KRYS
Price
$147.61
Change
-$2.39 (-1.59%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
4.33B
17 days until earnings call
Interact to see
Advertisement

IDYA vs KRYS

Header iconIDYA vs KRYS Comparison
Open Charts IDYA vs KRYSBanner chart's image
IDEAYA Biosciences
Price$24.50
Change-$0.33 (-1.33%)
Volume$5.48K
Capitalization2.17B
Krystal Biotech
Price$147.61
Change-$2.39 (-1.59%)
Volume$2.21K
Capitalization4.33B
IDYA vs KRYS Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. KRYS commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and KRYS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (IDYA: $24.83 vs. KRYS: $150.00)
Brand notoriety: IDYA and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 194% vs. KRYS: 57%
Market capitalization -- IDYA: $2.17B vs. KRYS: $4.33B
IDYA [@Biotechnology] is valued at $2.17B. KRYS’s [@Biotechnology] market capitalization is $4.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • KRYS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +12.40% price change this week, while KRYS (@Biotechnology) price change was -0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.76%. For the same industry, the average monthly price growth was +19.76%, and the average quarterly price growth was +29.65%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

KRYS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+8.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.34B) has a higher market cap than IDYA($2.18B). IDYA YTD gains are higher at: -3.385 vs. KRYS (-4.251). KRYS has higher annual earnings (EBITDA): 140M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. KRYS (617M). KRYS has less debt than IDYA: KRYS (9.66M) vs IDYA (26M). KRYS has higher revenues than IDYA: KRYS (333M) vs IDYA (7M).
IDYAKRYSIDYA / KRYS
Capitalization2.18B4.34B50%
EBITDA-356.46M140M-255%
Gain YTD-3.385-4.25180%
P/E RatioN/A35.97-
Revenue7M333M2%
Total Cash693M617M112%
Total Debt26M9.66M269%
FUNDAMENTALS RATINGS
IDYA vs KRYS: Fundamental Ratings
IDYA
KRYS
OUTLOOK RATING
1..100
1618
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
7436
SMR RATING
1..100
9457
PRICE GROWTH RATING
1..100
5360
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (63) in the null industry is in the same range as KRYS (70) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for IDYA (74) in the null industry. This means that KRYS’s stock grew somewhat faster than IDYA’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for IDYA (94) in the null industry. This means that KRYS’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Price Growth Rating (53) in the null industry is in the same range as KRYS (60) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that KRYS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAKRYS
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
77%
Bearish Trend 26 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDDAX10.36N/A
N/A
MassMutual Diversified Value A
QRSVX43.22N/A
N/A
FPA Queens Road Small Cap Value Inv
GREUX12.25N/A
N/A
Goldman Sachs Real Estate Securities R6
CUSUX19.05N/A
N/A
Six Circles U.S. Unconstrained Equity
JORRX19.96-0.04
-0.20%
Janus Henderson Global Select R

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with CGON. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+5.08%
CGON - IDYA
62%
Loosely correlated
-0.68%
IMNM - IDYA
61%
Loosely correlated
-1.83%
SYRE - IDYA
60%
Loosely correlated
-1.18%
NRIX - IDYA
60%
Loosely correlated
-0.86%
CRNX - IDYA
58%
Loosely correlated
-1.84%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-2.12%
XNCR - KRYS
56%
Loosely correlated
-3.45%
CRNX - KRYS
56%
Loosely correlated
-1.84%
IDYA - KRYS
56%
Loosely correlated
+5.08%
ACLX - KRYS
55%
Loosely correlated
+0.43%
SYRE - KRYS
54%
Loosely correlated
-1.18%
More